UNSPSC 51392504: Carbazeran

This classification denotes a phosphodiesterase inhibitor with the molecular formula C18H24N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0N4I6K95P2, chemically known as 1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidyl ethylcarbamate but generally known as carbazeran, which bears US NIH Compound Identifier 71983. European Medicines Agency schedules Carbazeran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06118MIG.

UNSPSC 51392504 Carbazeran is a Commodity code that encompasses pharmaceutical products and related health-system supplies procured by state and local public health and human services agencies. The recent opportunities tagged under this code show activity in naloxone procurement and direct-to-manufacturer prescription program development, though the naloxone work represents a supply-chain commodity purchase while the Texas HHS therapeutic pharmacy initiative represents a more complex service-integration procurement. State and local demand under this code appears driven primarily by public health departments and human services commissions pursuing community health initiatives, substance-abuse response programs, and pharmacy benefit optimization. Issuing bodies include county health systems (Seminole County, Florida) and state health and human services commissions (Texas Health and Human Services Commission), suggesting the code captures both routine pharmaceutical procurement and strategic health-system modernization efforts.

Activity is concentrated in Florida and Texas based on recent solicitations. Seminole County posted an IFB (IFB60459723LAS) on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the initial term is two years with a one-year renewal option and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026, to solicit vendor capabilities for direct-to-manufacturer prescription programs designed to improve pharmacy benefit efficiency and cost management. No other recent state or local opportunities under this code appear in the source, suggesting limited current activity or a mismatch between the code's nominal pharmaceutical scope and recent procurement practices in this space.